USNAConsumer Defensive · Packaged FoodsTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 85 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores USANA Health Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (25): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on USNA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Feb 2025 | DA Davidson | Maintains | Neutral | $38 → $36 |
| 27 Feb 2025 | DA Davidson | Maintains | Neutral | — |
| 2 Jan 2025 | DA Davidson | Maintains | Neutral | — |
| 23 Oct 2024 | DA Davidson | Maintains | Neutral | — |
| 25 July 2024 | DA Davidson | Maintains | Neutral | — |
| 7 May 2024 | DA Davidson | Maintains | Neutral | — |
| 22 Feb 2024 | DA Davidson | Maintains | Neutral | — |
| 25 Oct 2023 | DA Davidson | Maintains | Neutral | — |
| 26 Apr 2023 | DA Davidson | Maintains | Neutral | — |
| 13 Feb 2023 | DA Davidson | Maintains | Neutral | — |
| 27 Oct 2022 | DA Davidson | Maintains | Neutral | — |
| 28 July 2022 | DA Davidson | Maintains | Neutral | — |
| 12 July 2022 | DA Davidson | Maintains | Neutral | — |
| 7 July 2022 | Jefferies | Downgrade | Underperform | — |
| 27 Apr 2022 | DA Davidson | Maintains | Neutral | — |
| 14 Apr 2022 | DA Davidson | Initiates | Neutral | — |
| 10 Feb 2021 | Roth Capital | Maintains | Buy | — |
| 17 Dec 2020 | Roth Capital | Initiates | Buy | — |
| 22 Aug 2019 | Jefferies | Initiates | Hold | — |
| 3 July 2019 | Sidoti & Co. | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
USNA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, USANA Health Sciences, Inc. returned −30.3% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 28% of US stocks
Cheaper than 88% of US stocks
Cheaper than 83% of US stocks
Cheaper than 57% of US stocks
Higher than 20% of US stocks
Higher than 30% of US stocks
Higher than 90% of US stocks
Higher than 53% of US stocks
Higher than 27% of US stocks
Higher than 39% of US stocks
Higher than 69% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
USANA Health Sciences, Inc. has a market value of $264.8M and an enterprise value of $150.9M.
Revenue in the twelve months to 30 June 2026: $913.4M. The latest quarter shrank 5.3% year on year.
Net income over the same four quarters: −$29.2M, a −3.2% net margin.
Diluted earnings per share, trailing twelve months: $−1.21.
Free cash flow in the twelve months to 30 June 2026: $15.9M.
USANA Health Sciences, Inc. spent $0.0 on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 27.3×; forward P/E: 8.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
USANA Health Sciences, Inc. employs 1,570 people — $582K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own USANA Health Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
USANA held its third-quarter 2026 earnings conference call on November 4, 2026, with company executives and one conference-call participant listed. The provided excerpt contains only the call opening and participant information.
Why it matters — The excerpt confirms a quarterly earnings call took place but provides no results or management commentary for USNA watchers to assess.
USANA Health Sciences reported a quarterly loss of $0.11 per share, compared with the Zacks consensus estimate of a loss of $0.11. A year earlier, it reported a loss of $0.15 per share.
Why it matters — The report gives USNA watchers an update on quarterly earnings relative to consensus and the prior-year period.
USANA reported third-quarter 2026 net sales of $206 million, compared with $214 million a year earlier. Net loss was $5.6 million versus $6.5 million, diluted EPS was $(0.30) versus $(0.36), adjusted diluted EPS was $(0.11) versus $(0.15), and adjusted EBITDA was $12.1 million versus $13.8 million.
Why it matters — The results show lower year-over-year sales and adjusted EBITDA alongside narrower losses and improved per-share loss measures, offering investors an update on USANA’s quarterly performance.
USANA announced that its BiOmega omega-3 supplement again earned ConsumerLab’s Seal of Approval after testing through the company’s Quality Certification Program. The testing was the same applied to omega-3 products selected for ConsumerLab’s 2026 review.
Why it matters — The approval provides third-party validation of BiOmega’s quality, purity, and label accuracy, areas relevant to USANA’s product reputation.
USANA Chairman and CEO Kevin Guest urged people to measure success beyond income, career achievements, and possessions, emphasizing meaningful experiences, relationships, and lessons as Thanksgiving approaches.
Why it matters — The item highlights the CEO’s public messaging and leadership profile, but does not report a company operational or financial development.
As at 4 Nov 2026, USANA Health Sciences, Inc. ranks 85 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No analyst covering USANA Health Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for USNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $25 to $25 over the next 12 months.
USANA Health Sciences, Inc. returned -30.3% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
USANA Health Sciences Inc. is a direct-selling health and wellness company that develops, manufactures, and distributes science-based nutritional supplements, healthy foods, and personal care products.
The most recent item we track (Seeking Alpha, 4 Nov 2026): "USANA Health Sciences, Inc. (USNA) Q3 2026 Earnings Call Transcript". USANA held its third-quarter 2026 earnings conference call on November 4, 2026, with company executives and one conference-call participant listed. The provided excerpt contains only the call opening and participant information.
USANA Health Sciences Inc. is a direct-selling health and wellness company that develops, manufactures, and distributes science-based nutritional supplements, healthy foods, and personal care products. USANA Health Sciences Inc. serves consumers through a network of independent distributors and direct-to-consumer channels, offering products that support daily nutrition, active lifestyles, weight management, and skincare. Its portfolio includes nutritional optimizers, vitamin and mineral formulas, meal-replacement products, probiotics, omega-based supplements, and skincare regimens designed for a variety of personal care needs. The company also operates a children’s wellness business through Hiya, broadening its reach in family nutrition. With operations across Asia Pacific, the Americas, and Europe, USANA Health Sciences Inc. plays a role in the global consumer health market by combining in-house product development, manufacturing, and international distribution.
CEO Mr. Kevin G. Guest · 1,570 employees · United States · https://www.usana.com
